Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children

被引:0
|
作者
Nagatoshi, Y [1 ]
Okamura, J [1 ]
Ikuno, Y [1 ]
Akamatsu, M [1 ]
Tasaka, H [1 ]
机构
[1] KYUSHU NATL CANC CTR,SECT PEDIAT,MINAMI KU,FUKUOKA 815,JAPAN
关键词
allogeneic bone marrow transplantation; children; intensified conditioning regimen; myelodysplastic syndrome;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ten children with myelodysplastic syndrome underwent an allogeneic bone marrow transplantation (BMT) with an intensified conditioning regimen. The median age of the patients was 8 years (range 2-10), and included 6 males and 4 females. The subtype of the disease was refractory anemia (RA) in 4, RA with excess blasts (RAEB) in 4, RAEB in transformation (RAEB-T) in 1, and juvenile chronic myelogenous leukemia (JCML) in 1. All patients were conditioned with high-dose cytosine arabinoside (12 000 mg/m(2)), cyclophosphamide (120 mg/kg) and either total body irradiation (10-13.2 Gy) or busulfan (16 mg/kg or 560 mg/m(2)). Cyclosporine A and/or methotrexate were used for the prophylaxis of graft-versus-host disease (GVHD). Engraftment was prompt in all but one patient. Severe acute GVHD (grade 3) (n = 1), interstitial pneumonitis (n = 1) and veno-occlusive disease of the liver (n = 1) occurred. The disease relapsed in one patient with RAEB-T. Seven of the 10 patients were alive and disease free 2-74 months after BMT. The disease-free survival rate at 4 years was 69 +/- 15%. All surviving patients were in the full performance status. The examined children with MDS tolerated this intensified conditioning regimen well. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [31] Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation
    AA Maschan
    OI Kryzanovskii
    MI Yourlova
    EV Skorobogatova
    ED Pashanov
    YE Potapova
    LA Timonova
    NY Bogatcheva
    EV Samochatova
    AG Roumjantzev
    Bone Marrow Transplantation, 1997, 19 : 385 - 387
  • [32] Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation
    Maschan, AA
    Kryzanovskii, OI
    Yourlova, MI
    Skorobogatova, EV
    Pashanov, ED
    Potapova, YE
    Timonova, LA
    Bogatcheva, NY
    Samochatova, EV
    Roumjantzev, AG
    BONE MARROW TRANSPLANTATION, 1997, 19 (04) : 385 - 387
  • [33] HIGH-DOSE CYTOSINE-ARABINOSIDE, TOTAL-BODY IRRADIATION AND MARROW TRANSPLANTATION FOR ADVANCED MALIGNANT-LYMPHOMA
    PETERSEN, FB
    APPELBAUM, FR
    BIGELOW, CL
    BUCKNER, CD
    CLIFT, RA
    SANDERS, JE
    STORB, R
    SULLIVAN, KM
    WEIDEN, PL
    FEFER, A
    THOMAS, ED
    BONE MARROW TRANSPLANTATION, 1989, 4 (05) : 483 - 488
  • [34] ETOPOSIDE IN COMBINATION WITH CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION OR BUSULFAN AS CONDITIONING FOR MARROW TRANSPLANTATION IN ADULTS AND CHILDREN
    SPITZER, TR
    PETERS, C
    ORTLIEB, M
    TEFFT, MC
    TORRISI, J
    CAHILL, R
    GADNER, H
    URBAN, C
    DEEG, HJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (01): : 39 - 44
  • [35] SIMULTANEOUS INFUSION OF HIGH-DOSE CYTOSINE-ARABINOSIDE WITH CYCLOPHOSPHAMIDE FOLLOWED BY TOTAL-BODY IRRADIATION AND MARROW INFUSION FOR THE TREATMENT OF PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCY
    PETERSEN, FB
    APPELBAUM, FR
    BUCKNER, CD
    SANDERS, JE
    CLIFT, RA
    MCGUFFIN, R
    BEARMAN, SI
    FLOURNOY, N
    THOMAS, ED
    BONE MARROW TRANSPLANTATION, 1988, 3 (06) : 619 - 624
  • [36] Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation
    RB Geller
    SM Devine
    K O’Toole
    L Persons
    J Keller
    D Mauer
    HK Holland
    SP Dix
    M Piotti
    I Redei
    G Connaghan
    LT Heffner
    CD Hillyer
    EK Waller
    EF Winton
    JR Wingard
    Bone Marrow Transplantation, 1997, 20 : 219 - 225
  • [37] Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation
    Geller, RB
    Devine, SM
    OToole, K
    Persons, L
    Keller, J
    Mauer, D
    Holland, HK
    Dix, SP
    Piotti, M
    Redei, I
    Connaghan, G
    Heffner, LT
    Hillyer, CD
    Waller, EK
    Winton, EF
    Wingard, JR
    BONE MARROW TRANSPLANTATION, 1997, 20 (03) : 219 - 225
  • [38] Busulfan vs total body irradiation combined with cyclophosphamide as conditioning for autologous or allogeneic bone marrow transplantation in patients with Acute Leukemia.
    Labopin, M
    Ringden, O
    Mandelli, F
    Tura, S
    Iriondo, A
    Haas, R
    Gluckman, E
    Gorin, NC
    BLOOD, 1995, 86 (10) : 361 - 361
  • [39] Efficacy of High-Dose Cytarabine Added to Cyclophosphamide/Total-Body Irradiation in the Conditioning Regimen of Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancy
    Arai, Yasuyuki
    Aoki, Kazunari
    Takeda, June
    Kondo, Tadakazu
    Eto, Tetsuya
    Ota, Shuichi
    Hashimoto, Hisako
    Fukuda, Takahiro
    Ozawa, Yukiyasu
    Kanda, Yoshinobu
    Kato, Chiaki
    Kurokawa, Mineo
    Iwato, Koji
    Onizuka, Makoto
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Takami, Akiyoshi
    BLOOD, 2015, 126 (23)
  • [40] High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia
    Sato, N
    Furukawa, T
    Kuroha, T
    Hashimoto, S
    Masuko, M
    Takahashi, H
    Yano, T
    Abe, T
    Fuse, I
    Koike, T
    Kishi, K
    Aizawa, Y
    BONE MARROW TRANSPLANTATION, 2004, 34 (04) : 299 - 303